NASDAQ:AXDX Accelerate Diagnostics (AXDX) Stock Price, News & Analysis $1.30 +0.07 (+5.69%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.22▼$1.3050-Day Range$0.87▼$1.4752-Week Range$0.73▼$7.58Volume45,341 shsAverage Volume93,339 shsMarket Capitalization$28.67 millionP/E RatioN/ADividend YieldN/APrice Target$1.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Accelerate Diagnostics alerts: Email Address Accelerate Diagnostics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside23.1% Downside$1.00 Price TargetShort InterestHealthy4.98% of Float Sold ShortDividend StrengthN/ASustainability-1.62Upright™ Environmental ScoreNews Sentiment0.52Based on 4 Articles This WeekInsider TradingSelling Shares$318 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.37) to ($1.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.01 out of 5 starsMedical Sector408th out of 936 stocksAnalytical Instruments Industry12th out of 27 stocks 1.3 Analyst's Opinion Consensus RatingAccelerate Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAccelerate Diagnostics has received no research coverage in the past 90 days.Read more about Accelerate Diagnostics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.98% of the float of Accelerate Diagnostics has been sold short.Short Interest Ratio / Days to CoverAccelerate Diagnostics has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Accelerate Diagnostics has recently decreased by 3.39%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAccelerate Diagnostics does not currently pay a dividend.Dividend GrowthAccelerate Diagnostics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAccelerate Diagnostics has received a 74.73% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Diagnostic test kits" product. See details.Environmental SustainabilityThe Environmental Impact score for Accelerate Diagnostics is -1.62. Previous Next 2.5 News and Social Media Coverage News SentimentAccelerate Diagnostics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Accelerate Diagnostics this week, compared to 1 article on an average week.Search Interest1 people have searched for AXDX on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Accelerate Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $318.00 in company stock.Percentage Held by Insiders43.60% of the stock of Accelerate Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 17.14% of the stock of Accelerate Diagnostics is held by institutions.Read more about Accelerate Diagnostics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Accelerate Diagnostics are expected to grow in the coming year, from ($2.37) to ($1.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Accelerate Diagnostics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Accelerate Diagnostics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Accelerate Diagnostics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About Accelerate Diagnostics Stock (NASDAQ:AXDX)Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.Read More AXDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXDX Stock News HeadlinesJuly 25 at 1:24 AM | americanbankingnews.comAccelerate Diagnostics (NASDAQ:AXDX) Earns Hold Rating from Analysts at StockNews.comJuly 24 at 1:13 PM | finance.yahoo.comAirbyte Joins AWS ISV Accelerate ProgramJuly 26, 2024 | Crypto 101 Media (Ad)Brace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.July 23 at 5:08 PM | msn.comAccelerate’s funders agree to further financing while asset disposal program to reduce debt continuesJuly 17, 2024 | americanbankingnews.comAccelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated by Analysts at StockNews.comJuly 16, 2024 | americanbankingnews.comAccelerate Diagnostics, Inc. (NASDAQ:AXDX) Sees Significant Increase in Short InterestJune 13, 2024 | investorplace.comDead Cat Bounce: 3 Stocks to Sell Before They Plunge AgainMay 10, 2024 | washingtonpost.comTruBridge: Q1 Earnings SnapshotJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 9, 2024 | markets.businessinsider.comAccelerate Diagnostics Reports Q1 Loss, Misses Revenue EstimatesMay 9, 2024 | finance.yahoo.comAccelerate Diagnostics, Inc. (NASDAQ:AXDX) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finanznachrichten.deAccelerate Diagnostics, Inc.: Accelerate Diagnostics Reports Preliminary First Quarter 2024 Financial ResultsMay 9, 2024 | finance.yahoo.comAccelerate Diagnostics Inc (AXDX) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...May 9, 2024 | finance.yahoo.comQ1 2024 Accelerate Diagnostics Inc Earnings CallMay 8, 2024 | investorplace.comAXDX Stock Earnings: Accelerate Diagnostics Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | prnewswire.comAccelerate Diagnostics Reports Preliminary First Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comAccelerate Diagnostics earnings preview: what to expectMay 2, 2024 | prnewswire.comAccelerate Diagnostics Scheduled Call to Review 2024 First Quarter Results.See More Headlines Receive AXDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:AXDX CUSIPN/A CIK727207 Webacceleratediagnostics.com Phone(520) 365-3100Fax520-269-6580Employees220Year FoundedN/APrice Target and Rating Average Stock Price Target$1.00 High Stock Price Target$1.00 Low Stock Price Target$1.00 Potential Upside/Downside-23.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($4.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-61,620,000.00 Net Margins-452.28% Pretax Margin-503.92% Return on EquityN/A Return on Assets-205.15% Debt Debt-to-Equity RatioN/A Current Ratio1.50 Quick Ratio1.29 Sales & Book Value Annual Sales$12.06 million Price / Sales2.38 Cash FlowN/A Price / Cash FlowN/A Book Value($1.37) per share Price / Book-0.95Miscellaneous Outstanding Shares22,050,000Free Float12,437,000Market Cap$28.67 million OptionableOptionable Beta0.57 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Jack Phillips (Age 58)CEO, President & Director Comp: $595kMr. David Patience (Age 38)Chief Financial Officer Comp: $285.27kMr. Lawrence Michael Mertz (Age 61)Chief Technology Officer Comp: $335.94kMs. Maya GowriSenior VP & Head of OperationsLaura PiersonInvestor Relations OfficerMr. John MeduriChief Strategy OfficerMr. Chris ThodeSenior Vice President of US CommercialMs. Rita BoukamelSenior VP & Head of EMEAMore ExecutivesKey CompetitorsSyntec OpticsNASDAQ:OPTXOptex SystemsNASDAQ:OPXSClearSign TechnologiesNASDAQ:CLIRBionano GenomicsNASDAQ:BNGOAutoscope TechnologiesNASDAQ:AATCView All CompetitorsInsiders & InstitutionsGriffin Asset Management Inc.Bought 26,400 shares on 7/23/2024Ownership: 6.261%Larry Michael MertzSold 361 sharesTotal: $317.68 ($0.88/share)Oracle Investment Management Inc.Sold 69,474 shares on 5/15/2024Ownership: 0.194%Jack PhillipsSold 26,735 sharesTotal: $20,853.30 ($0.78/share)Jack PhillipsSold 26,545 sharesTotal: $22,828.70 ($0.86/share)View All Insider TransactionsView All Institutional Transactions AXDX Stock Analysis - Frequently Asked Questions How have AXDX shares performed this year? Accelerate Diagnostics' stock was trading at $3.92 at the beginning of the year. Since then, AXDX shares have decreased by 66.8% and is now trading at $1.30. View the best growth stocks for 2024 here. How were Accelerate Diagnostics' earnings last quarter? Accelerate Diagnostics, Inc. (NASDAQ:AXDX) issued its quarterly earnings results on Wednesday, May, 8th. The medical research company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.72) by $0.16. The medical research company earned $2.92 million during the quarter, compared to analysts' expectations of $3 million. When did Accelerate Diagnostics' stock split? Accelerate Diagnostics's stock reverse split on the morning of Wednesday, July 12th 2023. The 1-10 reverse split was announced on Wednesday, July 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Accelerate Diagnostics' major shareholders? Top institutional shareholders of Accelerate Diagnostics include Griffin Asset Management Inc. (6.26%). Insiders that own company stock include Jack Phillips, Larry Michael Mertz, David Patience, Steven Reichling, Ron Price, Hany Massarany and Jack W Schuler. View institutional ownership trends. How do I buy shares of Accelerate Diagnostics? Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Accelerate Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL) and Alibaba Group (BABA). This page (NASDAQ:AXDX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Accelerate Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Accelerate Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
